Low dose selegiline (L‐Deprenyl) in social phobia

Simpson, H. Blair; Schneier, Franklin R.; Marshall, Randall D.; Campeas, Raphael; Vermes, Donna; Silvestre, João Paulo; Davies, Sharon; Liebowitz, Michael R.

doi:10.1002/(sici)1520-6394(1998)7:3<126::aid-da5>3.3.co;2-9

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As we mentioned previously in a study of a different cohort [20], our PET data may indicate dopaminergic dysfunction in SAD similar to at least some subgroups of treatment resistant depression for which dopamine agonists could be effective [79]. However, dopaminergic medications have not stood out as particularly effective on their own, although this topic is understudied [80,81]. In all evaluated brain regions, there was positive coexpression of SERT and DATs at baseline which exhibited a positive relation with symptom severity.…”

Section: Discussionsupporting

confidence: 61%

Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy

et al. 2022

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors (SSRIs) and internet-based cognitive behavioral therapy (ICBT) are recommended treatments of social anxiety disorder (SAD), and often combined, but their effects on monoaminergic signaling are not well understood. In this multi-tracer positron emission tomography (PET) study, 24 patients with SAD were randomized to treatment with escitalopram+ICBT or placebo+ICBT under double-blind conditions. Before and after 9 weeks of treatment, patients were examined with positron emission tomography and the radioligands [11C]DASB and [11C]PE2I, probing the serotonin (SERT) and dopamine (DAT) transporter proteins respectively. Both treatment combinations resulted in significant improvement as measured by the Liebowitz Social Anxiety Scale (LSAS). At baseline, SERT-DAT co-expression was high and, in the putamen and thalamus, co-expression showed positive associations with symptom severity. SERT-DAT co-expression was also predictive of treatment success, but predictor-outcome associations differed in direction between the treatments. After treatment, average SERT occupancy in the SSRI + ICBT group was >80%, with positive associations between symptom improvement and occupancy in the nucleus accumbens, putamen and anterior cingulate cortex. Following placebo+ICBT, SERT binding increased in the raphe nuclei. DAT binding increased in both groups in limbic and striatal areas, but relations with symptom improvement differed, being negative for SSRI + ICBT and positive for placebo + ICBT. Thus, serotonin-dopamine transporter co-expression exerts influence on symptom severity and remission rate in the treatment of social anxiety disorder. However, the monoamine transporters are modulated in dissimilar ways when cognitive-behavioral treatment is given concomitantly with either SSRI-medication or pill placebo.

show abstract

Section: Discussionsupporting

confidence: 61%

Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Response rate data from these unpublished studies were not available for review. Uncontrolled studies and reports of other drugs including venlafaxine (Altamura et al, 1999 ;Kelsey, 1995), nefazodone (Van Ameringen et al, 1999a ;Worthington et al, 1998), bupropion (Emmanuel et al, 1991), selegeline (Simpson et al, 1998b) and others have suggested beneficial effects in SAD, but controlled investigation is required before definitive conclusions can be drawn.…”

Section: Other Drugsmentioning

confidence: 99%

Social anxiety disorder in review: two decades of progress

Hidalgo

Barnett

Davidson

2001

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

Social anxiety disorder (SAD) is among the most common of all psychiatric disorders. It presents with a lifetime prevalence rate of up to 16 % in the general population and, like other anxiety disorders, is more frequent in women. Patients with SAD suffer from considerable psychiatric comorbidity that is often preceded by social anxiety. Social anxiety affects people early in life and provokes a great deal of impairment and cost, much being related to the under-recognition and\or under-treatment of this disorder, which occurs frequently with GPs and others specialists. There is a clear need among GPs for training and awareness about the existence of this disorder, its assessment, differential diagnosis and available treatments. In this paper we review the development of the concept of SAD and its epidemiology, and discuss the available information regarding cost and how SAD presents in primary-care settings. Potential aetiologies and studies concerning possible neurobiological mechanisms are also reviewed. Pharmacological and psychosocial treatments for SAD are examined and effect sizes calculated for placebo-controlled pharmacological studies of five medication categories.

show abstract

“…Small open‐label studies with nefazodone, bupropion and selegiline in SP have been disappointing (33–36).…”

Section: Drugs Of Limited Benefitmentioning

confidence: 99%

Pharmacotherapy of social phobia

Davidson

2003

Acta Psychiatr Scand

View full text Add to dashboard Cite

Objective: To review placebo‐controlled medication trials in social phobia (SP). Method: Published and/or presented placebo‐controlled trials of medication were reviewed and summarized. Results: Phenelzine is effective in 60–70% of patients with SP and always superior to placebo. Although reversible inhibitors of monoamine oxidase type A (RIMAs) are safer, their benefits are unpredictable. SSRIs, fluvoxamine, paroxetine and sertraline are superior to placebo in generalized SP. Gabergic drugs are useful, e.g. clonazepam, gabapentin and pregabalin. Promising effects have been found with venlafaxine, a serotonin–norepinephrine reuptake inhibitor, and the results of larger studies should be forthcoming in the next 2 years. Drugs such as buspirone, tricyclics and beta‐blockers are either ineffective or have limited use. SP is a chronic disorder, and early termination of successful pharmacotherapy is associated with a greater likelihood of relapse. Studies with paroxetine, clonazepam, sertraline and brofaromine show that continued treatment is associated with better maintenance of response. Special populations that require further study include children, those with comorbid Axis I disorders and the population with discrete (non‐generalized) SP. Conclusion: MAOI and SSRI are most uniformly effective in treating SP. Clonazepam and gabapentin may also be useful. Other drugs are of more limited value. Long‐term treatment is recommended to reduce rates of relapse.

show abstract

Low dose selegiline (L‐Deprenyl) in social phobia

Cited by 4 publications

References 0 publications

Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy

Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy

Social anxiety disorder in review: two decades of progress

Pharmacotherapy of social phobia

Contact Info

Product

Resources

About